Nature Search

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

In a phase 1b trial, treatment of patients with muscle-invasive bladder cancer with intravesical oncolytic virus cretostimogene grenadenorepvec in combination with nivolumab was safe and led to encouraging preliminary clinical response rates.

Roger Li
Nancy Y. Villa
Jose R. Conejo-Garcia
Research09 Nov 2024
Nature Medicine

Volume: 31, P: 176-188
Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

New treatments are needed for muscle invasive bladder cancers. Here, the authors show that combined Pparg activation and MEK inhibition using FDA approved drugs shrinks tumor volume and induces a Basal/Squamous-to-Luminal shift in the urothelium as well as in invading tumors.

Sakina A. Plumber
Tiffany Tate
Cathy Lee Mendelsohn
ResearchOpen Access02 Aug 2024
Nature Communications

Volume: 15, P: 1-16
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

Montserrat Garcia-Closas and colleagues report a genome-wide association study for bladder cancer. They identify three new susceptibility loci on chromosomes 22q13.1, 19q12 and 2q37.1.

Nathaniel Rothman
Montserrat Garcia-Closas
Stephen J Chanock
Research24 Oct 2010
Nature Genetics

Volume: 42, P: 978-984
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning

Zilong Bai
Mohamed Osman
Fei Wang
ResearchOpen Access22 Mar 2025
npj Digital Medicine

Volume: 8, P: 1-12
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

Xifeng Wu and colleagues show that a common variant in the prostate stem cell antigen (PSCA) gene on 8q24 is associated with susceptibility to urinary bladder cancer. The risk allele truncates the amino terminus of the PSCA gene product and reduces PSCA promoter activity in bladder cancer cell lines.

Xifeng Wu
Yuanqing Ye
Jian Gu
Research02 Aug 2009
Nature Genetics

Volume: 41, P: 991-995
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Neoadjuvant combination of immune checkpoint therapy in patients with cisplatin-ineligible bladder cancer achieves clinical efficacy and uncovers immune features as potential predictive biomarkers of treatment response.

Jianjun Gao
Neema Navai
Padmanee Sharma
Research12 Oct 2020
Nature Medicine

Volume: 26, P: 1845-1851
Assessment of Luminal and Basal Phenotypes in Bladder Cancer

Charles C. Guo
Jolanta Bondaruk
Bogdan Czerniak
ResearchOpen Access16 Jun 2020
Scientific Reports

Volume: 10, P: 1-14
Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer

Motoyuki Yamashita
Charles J Rosser
William F Benedict
Research24 Jul 2002
Cancer Gene Therapy

Volume: 9, P: 687-691
Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior

Aaron Mobley
Shizhen Zhang
Bogdan Czerniak
ResearchOpen Access19 Jan 2017
Scientific Reports

Volume: 7, P: 1-13
Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways

Jai-Hyun Kim
Tomasz Tuziak
Bogdan Czerniak
Research07 Mar 2005
Laboratory Investigation

Volume: 85, P: 532-549
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy

Tadeusz Majewski
Sangkyou Lee
Bogdan Czerniak
Research05 May 2008
Laboratory Investigation

Volume: 88, P: 694-721

Search

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial

Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning

Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Assessment of Luminal and Basal Phenotypes in Bladder Cancer

Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior

Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways

Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy

Search

Quick links

Search

Filter By:

Search

Quick links